Jianguo Zhi
Overview
Explore the profile of Jianguo Zhi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dai M, Chao T, Chiu C, Lu Y, Shiah H, Jackson C, et al.
Ther Adv Med Oncol
. 2023 Jul;
15:17588359231183680.
PMID: 37492633
Background: Paclitaxel is widely used for the treatment of metastatic breast cancer (MBC). However, it has a low oral bioavailability due to gut extrusion caused by P-glycoprotein (P-gp). Oral paclitaxel...
2.
Liang W, Geng R, Zhi J, Li J, Huang F
Materials (Basel)
. 2022 Feb;
15(4).
PMID: 35207891
Oxide metallurgy technology plays an important role in inclusion control and is also applied to improve the weldability of high strength steel. Based on the requirements of the weldability in...
3.
Wu L, Zhi J, Zhang J, Zhao B, Liu Q
Materials (Basel)
. 2021 Sep;
14(18).
PMID: 34576484
The effects of Cerium (Ce) were studied on the casting slab quality, microstructure, and inclusion evolution of cryogenic vessel steel. An optical metallographic microscope, scanning electron microscope, energy dispersive spectrometer,...
4.
Shapiro G, LoRusso P, Dowlati A, Do K, Jacobson C, Vaishampayan U, et al.
Br J Cancer
. 2020 Dec;
124(4):744-753.
PMID: 33311588
Background: Bromodomain and extra-terminal (BET) proteins are epigenetic readers that can drive carcinogenesis and therapy resistance. RO6870810 is a novel, small-molecule BET inhibitor. Methods: We conducted a Phase 1 study...
5.
Yee K, Papayannidis C, Vey N, Dickinson M, Kelly K, Assouline S, et al.
Leuk Res
. 2020 Dec;
100:106489.
PMID: 33302031
The prognosis remains poor for patients with relapsed or refractory (r/r) acute myeloid leukemia; thus, novel therapies are needed. We evaluated idasanutlin-a new, potent murine double minute 2 antagonist-alone or...
6.
Papai Z, Chen L, Costa D, Blotner S, Vazvaei F, Gleave M, et al.
Cancer Chemother Pharmacol
. 2019 May;
84(1):93-103.
PMID: 31062077
Purpose: Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic p53 activator with oral administration. To determine the need to conduct dedicated trial(s)...
7.
So W, Yang T, Yang X, Zhi J
Cancer Chemother Pharmacol
. 2018 Dec;
83(1):209-213.
PMID: 30511219
Purpose: Idasanutlin is a selective small-molecule MDM2 antagonist. It activates the tumor suppressor TP53 and is in phase 3 clinical trial for acute myeloid leukemia. Nonclinical studies have shown that...
8.
Blotner S, Chen L, Ferlini C, Zhi J
Cancer Chemother Pharmacol
. 2018 Feb;
81(3):597-607.
PMID: 29392451
Purpose: Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 activator. The aim of this analysis is to examine the potential...
9.
Nemunaitis J, Young A, Ejadi S, Miller W, Chen L, Nichols G, et al.
Cancer Chemother Pharmacol
. 2018 Jan;
81(3):529-537.
PMID: 29368050
Purpose: Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 activator. To optimize its dosing conditions, a number of clinical pharmacology...
10.
Wang K, Schaedeli Stark F, Schlothauer T, Lahr A, Cosson V, Zhi J, et al.
Cancer Chemother Pharmacol
. 2017 Mar;
79(4):661-671.
PMID: 28314990
Purpose: RO5323441 is a humanized anti-placental growth factor (PlGF) monoclonal antibody that has shown preclinical activity in several cancer models. The objective of this analysis is to examine the pharmacokinetic...